MAPK
As MAPKs são uma família de proteínas quinases envolvidas em uma variedade de processos celulares, incluindo crescimento, proliferação, diferenciação e respostas ao estresse. A via de sinalização MAPK consiste em várias camadas, incluindo ERK, JNK e p38 MAPKs, cada uma desempenhando papéis distintos na função celular. A desregulação da sinalização MAPK está ligada ao câncer, doenças inflamatórias e distúrbios metabólicos. Na CymitQuimica, oferecemos uma ampla gama de inibidores e ativadores de MAPK para apoiar sua pesquisa em biologia celular, transdução de sinais e mecanismos de doenças.
Foram encontrados 893 produtos para "MAPK". São mostrados os primeiros 500.
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
JNK3 inhibitor-8
JNK3 inhibitor-8: potent, selective, oral, BBB-penetrating, IC50: JNK3=21 nM, JNK2=2203 nM, JNK1>10,000 nM; potential in Alzheimer's research.Fórmula:C32H30FN7O3Cor e Forma:SolidPeso molecular:579.62G12Si-5
CAS:G12Si-5: covalent K-RasG12S inhibitor, Ki 26 μM, targets S-IIP domain, hinders oncogenic signaling, lowers ERK phosphorylation in mutant cells.Fórmula:C31H29ClFN5O3Cor e Forma:SolidPeso molecular:574.05LC 2 Epimer
CAS:Negative control for LC 2.Fórmula:C59H71ClFN11O7SCor e Forma:SolidPeso molecular:1132.8(S)-BAY-293
CAS:(S)-BAY-293 is a potent pan-KRAS inhibitor for the study of primary non-small lung and pancreatic cancers.Fórmula:C25H28N4O2SPureza:98%Cor e Forma:SolidPeso molecular:448.58GADGVGKSA
CAS:GADGVGKSA, a mutant KRAS G12D 9mer peptide, serves as an immunogenic neoantigen for cancer immunotherapy research [1].Fórmula:C30H52N10O13Cor e Forma:SolidPeso molecular:760.79XY-02-082
CAS:XY-02-082 is a covalent guanosine-mimetic inhibitor targeting G12C KRAS.Fórmula:C15H21ClF2N6O11P2Cor e Forma:SolidPeso molecular:596.76Deltasonamide 1 TFA
CAS:Deltasonamide 1 TFA: PDE6δ-KRas inhibitor, K D 203 pM, used in tumor research.Fórmula:C32H40ClF3N6O6S2Cor e Forma:SolidPeso molecular:761.28R18
CAS:14.3.3 protein antagonist, blocks binding to Raf-1/Bad/ASK1/exoenzyme S, competitive, no phosphorylation needed, KD ~80 nM.Fórmula:C101H157N27O29S3Pureza:98%Cor e Forma:SolidPeso molecular:2309.69PROTAC SOS1 degrader-5
CAS:PROTAC SOS1 degrader-5 (compound 4) serves as an effective degrader of PROTAC SOS1, exhibiting a DC50 of 13 nM. It robustly suppresses the proliferation of NCI-H358 cells, with an IC50 value of 5 nM [1].Fórmula:C45H51F3N8O7Cor e Forma:SolidPeso molecular:872.93KRpep-2d
CAS:KRpep-2d, a potent inhibitor of K-Ras, effectively suppresses the proliferation of cancer cells driven by K-Ras.Fórmula:C109H183N43O25S2Cor e Forma:SolidPeso molecular:2560.02StRIP16
Rab8a GTPase-binding stapled peptide (Kd = 12.7 μM). Cell permeable; localizes to the endomembrane system.Cor e Forma:SolidDB-10
DB-10 serves as a precursor to 3-nbutylphthalide (NBP). It is absorbed by cells in a temperature and energy-dependent manner through the pyrilamine cation transporter. DB-10 enhances cell survival and rapidly converts into an active form in vivo, increasing accumulation within the brain. This compound is applicable in ischemic stroke research.Cor e Forma:Odour SolidKinase Inhibitor Library
A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;Cor e Forma:Odour SolidRef: TM-L1600
1mgA consultar10μL*10mM (DMSO)A consultar20μL*10mM (DMSO)A consultar30μL*10mM (DMSO)A consultar50μL*10mM (DMSO)A consultar100μL*10mM (DMSO)A consultar250μL*10mM (DMSO)A consultar(RS)-G12Di-1
(RS)-G12Di-1 is a selective covalent inhibitor of K-Ras-G12D.Fórmula:C37H35FN6O4Cor e Forma:SolidPeso molecular:646.27038YN14
YN14 is a highly potent and selective KRASG12C proteolysis targeting chimera (PROTAC) capable of forming a stable KRASG12C: YN14: VHL ternary complex with lowPureza:98%Cor e Forma:Odour SolidSS47
CAS:SS47 is a PROTAC that degrades immunosuppressive HPK1 via proteasome; boosts BCMA CAR-T cell cancer therapy.Fórmula:C49H56N6O12SCor e Forma:SolidPeso molecular:953.07MAPK Inhibitor Library
A unique collection of 365 compounds targeting MAPK signaling for drug discovery in MAPK related diseases;Cor e Forma:Odour SolidRef: TM-L1400
1mgA consultar10μL*10mM (DMSO)A consultar20μL*10mM (DMSO)A consultar30μL*10mM (DMSO)A consultar50μL*10mM (DMSO)A consultar100μL*10mM (DMSO)A consultar250μL*10mM (DMSO)A consultarMRTF-A-IN-1
MRTF-A-IN-1 (compound 14) is an inhibitor of MRTF-A. It effectively suppresses cell proliferation and induces senescence in HCC cells.Fórmula:C22H21N3Cor e Forma:SolidPeso molecular:327.42KRASG12C IN-2
KRASG12C IN-2 (compound 17) is an orally active inhibitor of KRAS G12C, which effectively suppresses tumor growth in mice [1].Cor e Forma:SolidTagarafdeg
CAS:Tagarafdeg (CFT1946) is a PROTAC degradator targeting mutant BRAF, capable of degrading BRAF V600E, G469A, G466V mutations, anti proliferation.Fórmula:C45H49F2N11O9SPureza:99.34% - ＞99.99%Cor e Forma:SolidPeso molecular:958
